John Goudreau

Biography

 Dr. Goudreau received his medical degree and doctorate in neuropharmacology through the D.O.-Ph.D. Program at Michigan State University College of Osteopathic Medicine in 1995. He completed his residency in Neurology at the Mayo Clinic in 2000, where he was given the Mayo Brothers Distinguished Fellowship Award. After residency, Dr. Goudreau completed a Movement Disorders Fellowship at the Mayo Clinic, with a special interest in the genetics of movement disorders and advanced clinical training in the neurophysiology and botulinum toxin treatment of abnormal movements. Dr. Goudreau joined the MSU faculty in July of 2001 and continues his scientific and clinical interests in Parkinson’s disease and other movement disorders. His research will focus on Parkinson’s disease, including evaluation of potential genetic and environmental risk factors for Parkinson’s disease as well as developing effective neuroprotective and therapeutic drugs. He is Board certified in Neurology, and is an active member of the American Academy of Neurology, Movement Disorders Society, American Society for Pharmacology and Experimental Therapeutics, and the American Osteopathic Association. Dr. Goudreau is also Chair of the COMLEX Level I Committee of the National Board of Osteopathic Medical Examiners.

Research Interest

 Research Interests:  Neuroprotective treatments in Parkinson’s disease (PD) are needed to slow or halt the progressive deterioration of motor function that is associated with the relentless degeneration of nigrostriatal dopamine (DA) neurons. Advances in our understanding of the etiology and pathogenesis of PD have permitted the rational identification, pre-clinical testing, and selection of target compounds for testing in clinical trials. The overall goal of my research program at Michigan State University is to develop effective neuroprotective therapies for patients living with PD. To this end, I am pursuing a vertically integrated and translational approach that incorporates A) cutting-edge basic neuroscience research to identify novel neuroprotective targets, B) in vivo efficacy and safety screening of candidate neuroprotective compounds and C) clinical trials focused on neuroprotective therapies for patients with PD. The current research environment provides a golden opportunity to move beyond symptomatic treatment with DA replacement medications and towards therapy that has a truly enduring benefit for patients living with PD. Truly translational research requires the careful alignment of basic science investigation, pre-clinical testing and clinical trials to achieve the ultimate goal of effective neuroprotective treatments in PD. Please feel free to contact me if you have any questions about my research. Current Research Support 1 U10 NS053380-01 (NINDS) - Michigan State University Parkinson Disease Clinical Center R01 NS065338-01A2 (NINDS) - The role of parkin in selective dopamine neuronal degeneration INO-PD-P2-2008 Michael J. Fox Foundation - Safety of Urate Elevation in Parkinson’s Disease (SURE-PD) TVP 1012-501  Teva Pharmaceuticals  - Adagio Follow-up Study 1F31NS064783-01 Predoctoral NRSA for S. Pappas - All Diencephalospinal Dopamine Neurons and Restless Legs Syndrome 60025165 Michael J. Fox Foundation  - Safety, Tolerability and Efficacy Analysis of DYnacirc CR in Parkinson Disease (STEADY-PD)